Cybin (CYBN) showcases Helus Pharma at Jefferies Global Healthcare Conference
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Cybin Inc., operating as Helus Pharma, furnished a report noting that Interim CEO Eric So will join a fireside chat at the Jefferies Global Healthcare Conference in New York, held June 2–4, 2026. The session will be webcast live on June 4, 2026, at 2:35 p.m. EDT, with a replay available on the company’s investor relations site.
Helus Pharma is described as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at improving treatments for depression, anxiety and other mental health conditions. Its lead NSA, HLP003, is in Phase 3 clinical development for adjunctive treatment of major depressive disorder and has U.S. FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder. The release includes extensive forward-looking statement cautions and emphasizes that none of the company’s programs have yet been approved by regulators.
Positive
- None.
Negative
- None.
Key Figures
Conference dates: June 2–4, 2026
Fireside chat time: 2:35 p.m. EDT
Lead program stage: Phase 3
+1 more
4 metrics
Conference dates
June 2–4, 2026
Jefferies Global Healthcare Conference in New York
Fireside chat time
2:35 p.m. EDT
Webcast on June 4, 2026
Lead program stage
Phase 3
HLP003 for adjunctive treatment of major depressive disorder
Second program stage
Phase 2
HLP004 for generalized anxiety disorder
Key Terms
novel serotonergic agonists, Breakthrough Therapy Designation, Phase 3 clinical development, forward-looking statements, +2 more
6 terms
novel serotonergic agonists medical
"developing novel serotonergic agonists (“NSAs”), today announced that Eric So"
Breakthrough Therapy Designation regulatory
"HLP003, a proprietary NSA, in Phase 3 clinical development ... that has received Breakthrough Therapy Designation"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
Phase 3 clinical development medical
"HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment"
Phase 3 clinical development is the large, late-stage testing of a medical treatment in diverse patient populations to confirm whether it works, to gather more safety information, and to compare it with current standard treatments. Think of it like a final dress rehearsal before a product’s public launch: regulators rely on Phase 3 results to decide approval, so clear success can sharply increase a product’s commercial value while failure can materially reduce a company’s prospects.
forward-looking statements regulatory
"Certain statements in this news release ... are forward-looking statements or forward-looking information"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
major depressive disorder medical
"Phase 3 clinical development for the adjunctive treatment of major depressive disorder"
A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.
generalized anxiety disorder medical
"HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder"
Generalized anxiety disorder is a chronic mental health condition marked by persistent, excessive worry about everyday things that is hard to control and interferes with daily life. Think of it like a smoke alarm that stays on for weeks or months, making work, decision-making and productivity harder; for investors it matters because it drives demand for treatments, affects workforce performance and can influence regulatory scrutiny, clinical trial design and healthcare spending.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2026.
Commission File Number: 001-40673
Cybin Inc.
(Exact Name of Registrant as Specified in Charter)
100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CYBIN INC. | ||||||||||||||
| (Registrant) | ||||||||||||||
| Date: | June 1, 2026 | By: | /s/ Greg Cavers | |||||||||||
| Name: | Greg Cavers | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
EXHIBIT INDEX
| 99.1 | News Release dated June 1, 2026 | ||||
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
•Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT
NEW YORK & TORONTO – June 1, 2026 – Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Eric So, Helus Pharma’s Interim Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, taking place June 2-4, 2026.
The fireside chat will be webcast live on Thursday, June 4, 2026, at 2:35 p.m. EDT.
To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma’s investor relations website.
About Helus Pharma
Helus Pharma™, the commercial operating name of Cybin Inc. (the “Company” or “Helus Pharma”) is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs - novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus PharmaTM is a trademark of Cybin Corp.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2025, and the Company’s annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com
George Tziras
Chief Business Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com
Media Contact:
Johnny Tokarczyk
RXMD
Public Relations Director
jtokarczyk@rxmedyn.com
(914) 772-7562
FAQ
What event is Cybin (CYBN) highlighting in this Form 6-K?
Cybin, operating as Helus Pharma, is highlighting Interim CEO Eric So’s participation in a fireside chat at the Jefferies Global Healthcare Conference in New York, taking place June 2–4, 2026, with a webcast scheduled on June 4 at 2:35 p.m. EDT.
When will Helus Pharma’s Jefferies conference fireside chat be webcast?
The Helus Pharma fireside chat will be webcast live on June 4, 2026, at 2:35 p.m. EDT. A replay will later be available on the Events & Presentations page of the company’s investor relations website for interested investors and stakeholders.
What is Helus Pharma’s relationship to Cybin (CYBN)?
Helus Pharma is the commercial operating name of Cybin Inc. The filing explains that references to the company or Helus Pharma refer to Cybin, a clinical-stage pharmaceutical firm focused on proprietary novel serotonergic agonists for mental health conditions across several regions.
Which drug candidates is Helus Pharma currently developing?
Helus Pharma is developing HLP003, an NSA in Phase 3 clinical development for adjunctive treatment of major depressive disorder, and HLP004, an NSA in Phase 2 for generalized anxiety disorder. It also maintains a broader research portfolio of investigational NSA programs targeting mental health conditions.
Does HLP003 have any special regulatory status with the FDA?
Yes. HLP003, Helus Pharma’s lead NSA for adjunctive treatment of major depressive disorder, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This status is mentioned alongside its current Phase 3 clinical development stage in the company’s description.
What cautions does Cybin (Helus Pharma) provide about forward-looking statements?
The company warns that forward-looking statements involve risks and uncertainties that may cause actual results to differ materially. It cites macroeconomic conditions, market expectations, regulations, operations, and risk factors from prior MD&A and its annual information form, and states it assumes no duty to update these statements.
Have Helus Pharma’s NSA products like HLP003 and HLP004 been approved by regulators?
No. The company states that the U.S. Food and Drug Administration, Health Canada and similar regulators have not evaluated claims for NSAs or programs such as HLP003 and HLP004. It emphasizes efficacy is unconfirmed, rigorous research is needed, and lack of approvals could materially affect performance and operations.